Bone Total Assets from 2010 to 2024

BBLGW Stock

USD 60.50 0.00 0.00%

Bone Biologics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 2.3 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2008-03-31

Previous Quarter

3.8 M

Current Value

3.2 M

Quarterly Volatility

2.4 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Total Operating Expenses of 4.7 M or Gross Profit of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.

Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Bone Biologics Corp over the last few years. Total assets refers to the total amount of Bone Biologics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bone Biologics Corp books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Bone Biologics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 3.74 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Bone Total Assets Regression Statistics

	Arithmetic Mean	1,996,455
	Geometric Mean	0.00
	Coefficient Of Variation	132.50
	Mean Deviation	2,022,332
	Median	973,085
	Standard Deviation	2,645,305
	Sample Variance	7T
	Range	8.5M
	R-Value	0.56
	Mean Square Error	5.2T
	R-Squared	0.31
	Significance	0.03
	Slope	331,218
	Total Sum of Squares	98T

Bone Total Assets History

	2024	2.3 M
	2023	3.7 M
	2022	8.5 M
	2021	6.7 M
	2020	null
	2019	30.8 K
	2018	1 M

Other Fundumenentals of Bone Biologics Corp

Intangibles To Total Assets

Bone Biologics Total Assets component correlations

	Total Assets	Net Debt	Total Current Assets	Total Stockholder Equity	Retained Earnings	Total Liab	Common Stock	Short Term Debt	Accounts Payable	Net Receivables	Current Deferred Revenue	Long Term Debt	Net Invested Capital	Net Working Capital	Short Long Term Debt	Capital Stock
Total Assets		-0.65	1.0	0.62	-0.45	-0.25	-0.07	-0.31	-0.27	0.35	0.38	0.44	0.9	0.61	0.49	-0.58
Net Debt	-0.65		-0.66	-0.99	-0.02	0.89	0.73	0.82	0.34	0.21	0.01	-0.15	-0.8	-0.78	-0.28	0.7
Total Current Assets	1.0	-0.66		0.62	-0.45	-0.25	-0.07	-0.31	-0.27	0.35	0.38	0.44	0.9	0.61	0.49	-0.58
Total Stockholder Equity	0.62	-0.99	0.62		0.07	-0.92	-0.77	-0.83	-0.36	-0.27	-0.05	0.12	0.77	0.78	0.25	-0.7
Retained Earnings	-0.45	-0.02	-0.45	0.07		-0.35	-0.33	-0.37	-0.3	-0.87	-0.91	-0.83	-0.46	-0.02	-0.76	0.53
Total Liab	-0.25	0.89	-0.25	-0.92	-0.35		0.91	0.86	0.32	0.52	0.27	0.09	-0.49	-0.65	-0.04	0.53
Common Stock	-0.07	0.73	-0.07	-0.77	-0.33	0.91		0.7	0.18	0.53	0.21	-0.08	-0.3	-0.38	-0.17	0.48
Short Term Debt	-0.31	0.82	-0.31	-0.83	-0.37	0.86	0.7		0.21	0.63	0.49	0.24	-0.42	-0.68	0.06	0.52
Accounts Payable	-0.27	0.34	-0.27	-0.36	-0.3	0.32	0.18	0.21		0.12	0.22	0.23	-0.33	-0.53	0.3	-0.13
Net Receivables	0.35	0.21	0.35	-0.27	-0.87	0.52	0.53	0.63	0.12		0.89	0.68	0.35	-0.14	0.53	-0.14
Current Deferred Revenue	0.38	0.01	0.38	-0.05	-0.91	0.27	0.21	0.49	0.22	0.89		0.86	0.44	-0.05	0.75	-0.42
Long Term Debt	0.44	-0.15	0.44	0.12	-0.83	0.09	-0.08	0.24	0.23	0.68	0.86		0.51	-0.01	0.89	-0.57
Net Invested Capital	0.9	-0.8	0.9	0.77	-0.46	-0.49	-0.3	-0.42	-0.33	0.35	0.44	0.51		0.71	0.54	-0.71
Net Working Capital	0.61	-0.78	0.61	0.78	-0.02	-0.65	-0.38	-0.68	-0.53	-0.14	-0.05	-0.01	0.71		0.2	-0.58
Short Long Term Debt	0.49	-0.28	0.49	0.25	-0.76	-0.04	-0.17	0.06	0.3	0.53	0.75	0.89	0.54	0.2		-0.66
Capital Stock	-0.58	0.7	-0.58	-0.7	0.53	0.53	0.48	0.52	-0.13	-0.14	-0.42	-0.57	-0.71	-0.58	-0.66

Click cells to compare fundamentals

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	3.7 M	2.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

S	SentinelOne
MSFT	Microsoft
MSFT	Microsoft

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC